Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tu… Read more
Guardant Health Inc (GH) - Total Assets
Latest total assets as of December 2025: $2.01 Billion USD
Based on the latest financial reports, Guardant Health Inc (GH) holds total assets worth $2.01 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guardant Health Inc - Total Assets Trend (2016–2025)
This chart illustrates how Guardant Health Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Guardant Health Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Guardant Health Inc's total assets of $2.01 Billion consist of 72.8% current assets and 27.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.8% |
| Accounts Receivable | $137.85 Million | 6.9% |
| Inventory | $85.88 Million | 4.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $25.92 Million | 1.3% |
| Goodwill | $77.26 Million | 3.8% |
Asset Composition Trend (2016–2025)
This chart illustrates how Guardant Health Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guardant Health Inc's current assets represent 72.8% of total assets in 2025, a decrease from 88.4% in 2016.
- Cash Position: Cash and equivalents constituted 18.8% of total assets in 2025, down from 28.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.9% of total assets.
Guardant Health Inc Competitors by Total Assets
Key competitors of Guardant Health Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Guardant Health Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Guardant Health Inc generates 0.49x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Guardant Health Inc is currently not profitable relative to its asset base.
Guardant Health Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.84 | 4.68 | 21.29 |
| Quick Ratio | 4.56 | 4.36 | 20.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.16 Billion | $ 829.53 Million | $ 1.94 Billion |
Guardant Health Inc - Advanced Valuation Insights
This section examines the relationship between Guardant Health Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 55.67 |
| Latest Market Cap to Assets Ratio | 5.47 |
| Asset Growth Rate (YoY) | 35.5% |
| Total Assets | $2.01 Billion |
| Market Capitalization | $11.02 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Guardant Health Inc's assets at a significant premium ( 5.47x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Guardant Health Inc's assets grew by 35.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Guardant Health Inc (2016–2025)
The table below shows the annual total assets of Guardant Health Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.01 Billion | +35.54% |
| 2024-12-31 | $1.49 Billion | -16.84% |
| 2023-12-31 | $1.79 Billion | +10.96% |
| 2022-12-31 | $1.61 Billion | -26.97% |
| 2021-12-31 | $2.20 Billion | -2.96% |
| 2020-12-31 | $2.27 Billion | +136.02% |
| 2019-12-31 | $962.53 Million | +63.86% |
| 2018-12-31 | $587.40 Million | +71.29% |
| 2017-12-31 | $342.94 Million | +194.20% |
| 2016-12-31 | $116.56 Million | -- |